The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Size Increase Is Anticipated For The Guillain-Barre Syndrome Drugs Market Over The 2026–2030 Period?
The guillain-barre syndrome drugs market has experienced substantial growth in recent years. It is projected to expand from $1.25 billion in 2025 to $1.35 billion in 2026, showing a compound annual growth rate (CAGR) of 7.5%. Historically, the growth can be attributed to the established clinical effectiveness of IVIG therapy, the enduring use of plasma exchange in neurological disorders, the availability of corticosteroids for symptom management, the expansion of hospital neurology departments, and the increased recognition of GBS as a medical emergency.
The guillain-barre syndrome drugs market size is poised for robust expansion over the next few years. It is forecast to achieve a valuation of $1.73 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.5%. This anticipated growth during the forecast period stems from factors such as the increasing prevalence of autoimmune neurological disorders, enhanced understanding of post-infectious GBS instances, better availability of advanced hospital care, an expansion in IVIG manufacturing capabilities, and the requirement for rapid immune-modulating treatments in acute care. Prominent trends for the forecast period include the continued reliance on intravenous immunoglobulin as the initial line of treatment, an uptick in the utilization of plasma exchange for severe Guillain-Barre cases, an intensified focus on early detection and swift commencement of treatment, rising demand for intensive GBS management within hospitals, and the consistent application of supportive and supplementary drug therapies.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15581&type=smp
What Underlying Factors Are Accelerating The Growth Of The Guillain-Barre Syndrome Drugs Market?
The Guillain-Barré syndrome drugs market is projected to see growth driven by the increasing need for personalized medicine. Personalized medicine involves customizing medical treatments based on an individual’s genetic composition, biomarkers, or lifestyle factors, with the aim of boosting therapeutic effectiveness and minimizing negative side effects. The escalating demand for personalized medicine stems from progress in genomics, the increasing complexity of diseases, enhancements in diagnostic technologies, and robust regulatory support. The Guillain-Barré syndrome drugs market benefits from personalized medicine by facilitating customized treatment approaches that lead to improved patient outcomes and a reduction in complications often linked with general therapies. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the U.S. Food and Drug Administration (FDA) approved 16 new personalized therapies for patients with rare diseases in 2023, which is a significant rise from six therapies approved in 2022. Consequently, the growing demand for personalized medicine is a key factor propelling the expansion of the Guillain-Barré syndrome drugs market.
How Is The Guillain-Barre Syndrome Drugs Market Segmented Across Key Categories?
The guillain-barre syndrome drugs market covered in this report is segmented –
1) By Drug Class: Immunoglobulins (IVIG), Corticosteroids, Plasma Exchange
2) By Treatment Type: First-Line Treatment, Adjunctive Or Supportive Treatment
3) By Application: Clinic, Hospital, Other Applications
Subsegments:
1) By Immunoglobulins (Ivig): Intravenous Immunoglobulin (Ivig) Therapy, Human Normal Immunoglobulin (Hnig), Hyperimmune Immunoglobulin Products, Ivig Formulations For GBS Treatment
2) By Corticosteroids: Methylprednisolone, Prednisolone, Dexamethasone, Hydrocortisone, Betamethasone
3) By Plasma Exchange: Therapeutic Plasma Exchange (TPE), Plasmapheresis
Which Upcoming Trends Are Expected To Influence The Guillain-Barre Syndrome Drugs Market?
Leading companies in the Guillain-Barré syndrome (GBS) drugs market are prioritizing the development of innovative products, such as humanized monoclonal antibodies, to improve therapeutic precision, lessen immune-mediated nerve damage, and enhance their competitive standing. A humanized monoclonal antibody is defined as a laboratory-engineered antibody composed mainly of human antibody sequences, with a minor part derived from mouse or rat monoclonal antibodies, designed to target specific immune components involved in GBS pathology and to limit inflammation caused by complement. For example, in October 2023, Annexon Inc., a US-based clinical-stage biopharmaceutical company, announced that ANX005, a humanized monoclonal antibody that selectively inhibits C1q to prevent complement-driven neuronal injury in GBS, had received orphan drug designation from both the European Medicines Agency and the U.S. Food and Drug Administration. The company also reported completing target enrollment for its Phase 3 trial, with topline results anticipated in the first half of 2024, emphasizing ANX005’s potential to rapidly halt autoimmune damage and facilitate muscle strength recovery in affected patients.
Who Are The Dominant Players Shaping The Guillain-Barre Syndrome Drugs Market Landscape?
Major companies operating in the guillain-barre syndrome drugs market are CSL Behring LLC, Grifols SA, Octapharma AG, Takeda Pharmaceutical Company Limited, Biotest AG, Kedrion Biopharma Inc., Alexion Pharmaceuticals Inc., Argenx SE, Annexon Inc., Hansa Medical AB, F. Hoffmann-La Roche Ltd., Novartis AG, AbbVie Inc., Biogen Inc., Chugai Pharmaceutical Co. Ltd., Cadila Healthcare Limited, Akari Therapeutics Plc, Cellenkos Inc., Regenesance BV, Cresence AS
Read the full guillain-barre syndrome drugs market report here:
https://www.thebusinessresearchcompany.com/report/guillain-barre-syndrome-drugs-global-market-report
Which Region Is Projected To Dominate The Guillain-Barre Syndrome Drugs Market During The Forecast Period?
North America was the largest region in the guillain-barre syndrome drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the guillain-barre syndrome drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Guillain-Barre Syndrome Drugs Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=15581&type=smp
Browse Through More Reports Similar to the Global Guillain-Barre Syndrome Drugs Market 2026, By The Business Research Company
Guillain Barre Syndrome Market Report 2026
https://www.thebusinessresearchcompany.com/report/guillain-barre-syndrome-global-market-report
Central Nervous System Drug Market Report 2026
https://www.thebusinessresearchcompany.com/report/central-nervous-system-drug-global-market-report
Neurological Disorder Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/neurological-disorder-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model